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Ventricular assist surprise: Giant cell myocarditis or sarcoidosis?
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and Stephen R. Large, FRCS, Cambridge, United Kingdom
Idiopathic giant cell myocarditis (GCM) is a rapidly fatal disease with a worse naturalhistory than lymphocytic myocarditis.1 Transplantation is the best available therapy,despite the risk of disease recurrence in the allograft. However, patients with GCMoften die before a donor heart becomes available.2 Mechanical assist for acute myo-
carditis dramatically improves the natural history of the underlying disease. Particularly when
the picture is of lymphocytic myocarditis, there is a good chance of successful bridge to
recovery.3 There are no reported cases of bridge to recovery for GCM, and the world
experience of bridge to transplant totals 9 cases. Furthermore, the outcome of these patients
was poorer than that of other patients with GCM who underwent transplantation without prior
requirement of a ventricular assist device (VAD).2
Secondary GCM is associated with other systemic illnesses (eg, sarcoidosis).4 From a
clinical and pathologic standpoint, idiopathic GCM and cardiac sarcoidosis (CS) are consid-
ered different entities.5 We present a case that challenges this traditional view.
Clinical Summary
A 36-year-old previously healthy man presented to the local hospital with a 1-week history
of breathlessness and malaise. An echocardiogram showing a globally dilated heart, with a
left ventricular ejection fraction of 15%, confirmed the clinical diagnosis of acute failure.
Serial chest radiographs and comprehensive viral screens remained unremarkable throughout
his illness. His clinical condition deteriorated to cardiogenic shock, and he was referred to our
unit where a Thermo Cardiosystems HeartMate left VAD (Woburn, Mass) was inserted on an
emergency basis.
The left ventricular core biopsy was typical for GCM in its acute phase (Figure 1, A).
Although the literature suggests a beneficial effect for immunosuppression,1 this was kept in
reserve postoperatively because of ongoing infection. A pulmonary transbronchial biopsy
(obtained from the patient during bronchial toilet while he was still in intensive care)
demonstrated an appearance indicative of sarcoidosis (Figure 1, B). The patient was bridged
to transplantation, which took place uneventfully 87 days later. Analysis of the explanted
heart showed features of GCM in its healing phase but also persistent giant cells with an
appearance more typical of CS (Figure 1, C). Immunosuppression was routine with triple
cyclosporine-based therapy. Fifteen months posttransplantation, the patient remains free of
symptoms and of disease recurrence in the allograft.
Discussion
Differentiation of GCM from CS may be difficult, particularly when there is very limited
extracardiac involvement by sarcoidosis. The typical case of GCM presents with cardiac
failure. Histologically, there is myocyte necrosis without granuloma formation. Conversely,
CS is an interstitial granulomatosis presenting with arrhythmias or sudden death.5 The first
case of bridge to transplant for CS has only recently been described, showing that patients
with established sarcoidosis are less likely to require mechanical assist.6 The existing
classifications are based on small autopsy or in vivo studies. As opposed to Litovski and
colleagues’5 series of 15 autopsy cases, in which the 2 patterns of presentation were
described, Davidoff and colleagues4 did not find differences in the demographic, clinical, or
hemodynamic characteristics of patients in whom GCM or CS was diagnosed antemortem.
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From the larger series of the Multicenter GCM Study,1 it is
apparent that some patients die or are lost from follow-up before
serial histologic evaluation is possible. It is therefore not surprising
that a complex inflammatory and healing process is difficult to
characterize by a snapshot of tissue pathology. Clearly, some
patients are in the middle.7,8 We found a report in which a case
very similar to ours, with discrete sarcoidosis diagnosed on lung
autopsy tissue, was classified as CS.7 Perhaps GCM and CS
represent 2 ends of a disease spectrum. An analogy is possible with
the lung, in which the aggressive form of necrotizing sarcoid
granulomatosis is described.9
With the advent of ventricular assist, this speculation gains
more substance. The effect of hemodynamic unloading extends to
the level of cellular phenotype, with decreased susceptibility to
myocardial apoptosis and a reduction in the level of circulating
CD4 T cells.6,10 These changes are relevant for the cardiac recov-
ery of patients supported for myocarditis. In this context, one can
attempt to explain some of the distinguishing features of idiopathic
GCM and CS. The presence of myocyte necrosis, characteristic of
all forms of GCM, may indicate the early phase of a grave variant
of disease. If time were allowed, dead myocytes could be cleared
and granulomas could slowly organize. Fibrosis, a nonspecific
indicator of tissue damage and repair, could also become more
widespread. VADs possibly allow the more severely ill patients to
survive to a healing phase, when more typical pathology is dis-
cernible.
Until the pathology of this twilight zone is clarified, there are
practical implications. Patients with myocarditis who do not re-
quire a VAD urgently benefit from endomyocardial biopsy, be-
cause the type of pathology influences the prognosis and the choice
of device. In our patient, the diagnosis of pulmonary sarcoidosis
was incidental. When GCM is diagnosed in surgical candidates,
there is a case for actively excluding lung sarcoidosis by tissue
histology. Finally, the combination of immunosuppression and
mechanical support is better described for lymphocytic myocardi-
tis.11 Such novel combinations may also improve the poor out-
come of bridge to transplant in GCM, regardless of the primary or
secondary nature of the cause.
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Intraparenchymal replacement of the left pulmonary
artery with implantation of segmental arteries in a
26-year-old patient
Niyazi Cebi, MD, Fro¨mke Johannes, MD, Spiridon Botsios, MD, and Gerd Walterbusch,
MD, Dortmund, Germany
Aneurysms of the pulmonary artery are associated withprimary or secondary pulmonary hypertension,1chronic pulmonary embolism, or pulmonary valvestenosis.2 Systemic disorders, such as Behc¸et dis-
ease,3 Osler disease, and other acquired cardiovascular or congen-
ital diseases,4 are known to produce such aneurysms. Lethal com-
plications include bronchial rupture,3,4 dissections, and
intrapulmonary erosion. Compression of neighboring structures is
also a source of morbidity. We report on a patient who was
referred to our hospital after demonstration of bilateral, dilative
changes of the segmental arteries of the apicoposterior segments of
the upper lobes, as well as an aneurysm of the left pulmonary
artery of 3 cm in diameter at the bronchial bifurcation of the upper
and lower lobes (Figure 1). Additional aneurysms, including those
in the right lower lobe branches, were also observed. The surgical
procedure is discussed and described as a new lung parenchyma–
sparing technique.
Methods
A 26-year-old patient with confirmed Behc¸et disease and a week-
long history of hemoptysis was admitted to our hospital. The
patient had previously undergone treatment for uveitis and oral and
genital ulceration. A portion of the small intestine had also been
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Figure 1. Computed tomographic scan demonstrating aneurysm
of the left pulmonary artery at the bronchial bifurcation of the
upper and lower lobes.
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